UroGen Pharma Reiterates Anticipated FY23 Net Product Revenues From JELMYTO To Be In The Range Of $76M-$86M
Portfolio Pulse from Benzinga Newsdesk
UroGen Pharma has reaffirmed its forecast for FY23 net product revenues from JELMYTO, expecting them to be between $76 million and $86 million.
November 14, 2023 | 1:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UroGen Pharma expects FY23 net product revenues from JELMYTO to be in the range of $76M-$86M, indicating a positive outlook for the product's sales.
The reaffirmation of revenue guidance for JELMYTO by UroGen Pharma is a positive signal for investors, suggesting confidence in the product's market performance and potential for growth. This news is likely to be viewed favorably by the market, potentially leading to a short-term increase in URGN's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100